ABBOTT PARK, Ill., July 20, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023.
- Second-quarter GAAP diluted EPS of $0.78 and adjusted diluted EPS of $1.08, which excludes specified items.
- Projected full-year 2023 diluted EPS on a GAAP basis of $3.02 to $3.22.
- Projected full-year adjusted EPS of $4.30 to $4.50 remains unchanged but reflects an increased outlook for the underlying base business offset by a lower forecasted earnings contribution from COVID-19 testing-related sales.
- Abbott now projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales1, to be in the low double-digits2 and COVID-19 testing-related sales of approximately $1.3 billion.
- In May, Abbott received U.S. Food and Drug Administration (FDA) approval of its TactiFlex® Ablation Catheter, Sensor Enabled™, the world’s first ablation catheter with a unique flexible electrode tip and contact force sensing technology to treat patients with atrial fibrillation (AFib).
- In June, Abbott announced its FreeStyle Libre® 2 system is the first and only continuous glucose monitoring (CGM) system to receive expanded national reimbursement in France to now include all people with diabetes who use insulin.
- In June, Abbott received U.S. FDA approval of its AVEIR™ dual chamber (DR) leadless pacemaker system, the world’s first dual chamber leadless pacing system that treats people with abnormal heart rhythms.
“We’re achieving strong growth in our underlying base business,” said Robert B. Ford, chairman and chief executive officer, Abbott. “We expect our highly productive pipeline to sustain the momentum we’re building this year and position us well for growth in the future.”
SECOND-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange, the impact of exiting the pediatric nutrition business in China, and the impact of the acquisition of Cardiovascular Systems, Inc. (CSI) is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
|
Second Quarter 2023 Results (2Q23) |
|||||||||
|
Sales 2Q23 ($ in millions) |
Total Company |
Nutrition |
Diagnostics |
Established |
Medical Devices |
||||
|
U.S. |
3,758 |
881 |
961 |
— |
1,913 |
||||
|
International |
6,220 |
1,195 |
1,356 |
1,287 |
2,382 |
||||
|
Total reported |
9,978 |
2,076 |
2,317 |
1,287 |
4,295 |
||||
|
% Change vs. 2Q22 |
|||||||||
|
U.S. |
(23.2) |
15.7 |
(60.7) |
n/a |
13.3 |
||||
|
International |
(2.3) |
0.3 |
(26.8) |
5.2 |
13.6 |
||||
|
Total reported |
(11.4) |
6.3 |
(46.0) |
5.2 |
13.5 |
||||
|
Impact of foreign exchange |
(2.5) |
(3.0) |
(1.3) |
(7.4) |
(1.9) |
||||
|
Impact of CSI acquisition |
0.4 |
— |
— |
— |
1.2 |
||||
|
Impact of business exit |
(0.1) |
(0.6) |
— |
— |
— |
||||
|
Organic |
(9.2) |
9.9 |
(44.7) |
12.6 |
14.2 |
||||
|
Impact of COVID-19 testing sales (3) |
(20.7) |
— |
(51.8) |
— |
— |
||||
|
Organic (excluding COVID-19 tests) |
11.5 |
9.9 |
7.1 |
12.6 |
14.2 |
||||
|
U.S. |
10.9 |
15.7 |
5.2 |
n/a |
11.0 |
||||
|
International |
11.9 |
6.1 |
8.2 |
12.6 |
16.8 |
||||
|
First Half 2023 Results (1H23) |
|||||||||
|
Sales 1H23 ($ in millions) |
Total Company |
Nutrition |
Diagnostics |
Established |
Medical Devices |
||||
|
U.S. |
7,686 |
1,693 |
2,296 |
— |
3,691 |
||||
|
International |
12,039 |
2,350 |
2,709 |
2,476 |
4,504 |
||||
|
Total reported |
19,725 |
4,043 |
5,005 |
2,476 |
8,195 |
||||
|
% Change vs. 1H22 |
|||||||||
|
U.S. |
(21.8) |
17.7 |
(55.4) |
n/a |
14.2 |
||||
|
International |
(9.6) |
(2.4) |
(38.4) |
4.4 |
8.6 |
||||
|
Total reported |
(14.8) |
5.1 |
(47.6) |
4.4 |
11.0 |
||||
|
Impact of foreign exchange |
(2.9) |
(3.4) |
(1.6) |
(7.5) |
(2.9) |
||||
|
Impact of CSI acquisition |
0.2 |
— |
— |
— |
0.6 |
||||
|
Impact of business exit |
(0.2) |
(1.6) |
— |
— |
— |
||||
|
Organic |
(11.9) |
10.1 |
(46.0) |
11.9 |
13.3 |
||||
|
Impact of COVID-19 testing sales (3) |
(22.6) |
— |
(51.7) |
— |
— |
||||
|
Organic (excluding COVID-19 tests) |
10.7 |
10.1 |
5.7 |
11.9 |
13.3 |
||||
|
U.S. |
11.7 |
17.7 |
2.7 |
n/a |
12.9 |
||||
|
International |
10.2 |
5.4 |
7.5 |
11.9 |
13.7 |
||||
See table titled “Non-GAAP Revenue Reconciliation” for a reconciliation of adjusted historical revenue to reported revenue.
|
Nutrition |
|||||||
|
Second Quarter 2023 Results (2Q23) |
|||||||
|
Sales 2Q23 ($ in millions) |
Total |
Pediatric |
Adult |
||||
|
U.S. |
881 |
507 |
374 |
||||
|
International |
1,195 |
517 |
678 |
||||
|
Total reported |
2,076 |
1,024 |
1,052 |
||||
|
% Change vs. 2Q22 |
|||||||
|
U.S. |
15.7 |
22.5 |
7.6 |
||||
|
International |
0.3 |
1.1 |
(0.2) |
||||
|
Total reported |
6.3 |
10.6 |
2.5 |
||||
|
Impact of foreign exchange |
(3.0) |
(2.3) |
(3.5) |
||||
|
Impact of business exit |
(0.6) |
(1.6) |
— |
||||
|
Organic |
9.9 |
14.5 |
6.0 |
||||
|
U.S. |
15.7 |
22.5 |
7.6 |
||||
|
International |
6.1 |
7.5 |
5.2 |
||||
Worldwide Nutrition sales increased 6.3 percent on a reported basis and 9.9 percent on an organic basis in the second quarter. Refer to table titled “Condensed Consolidated Statement of Earnings” for a reconciliation of adjusted historical revenue to reported revenue.
In Pediatric Nutrition, global sales increased 10.6 percent on a reported basis and 14.5 percent on an organic basis. In the U.S., sales growth of 22.5 percent was primarily driven by continued market share recovery in the infant formula business following a voluntary recall of certain products last year.
In Adult Nutrition, global sales increased 2.5 percent on a reported basis and 6.0 percent on an organic basis, which was led by strong global growth of Ensure®, Abbott’s market-leading complete and balanced nutrition brand.
|
First Half 2023 Results (1H23) |
|||||||||
|
Sales 1H23 ($ in millions) |
Total |
Pediatric |
Adult |
||||||
|
U.S. |
1,693 |
966 |
727 |
||||||
|
International |
2,350 |
982 |
1,368 |
||||||
|
Total reported |
4,043 |
1,948 |
2,095 |
||||||
|
% Change vs. 1H22 |
|||||||||
|
U.S. |
17.7 |
28.6 |
5.8 |
||||||
|
International |
(2.4) |
(3.8) |
(1.4) |
||||||
|
Total reported |
5.1 |
9.9 |
1.0 |
||||||
|
Impact of foreign exchange |
(3.4) |
(2.6) |
(4.1) |
||||||
|
Impact of business exit |
(1.6) |
(3.8) |
— |
||||||
|
Organic |
10.1 |
16.3 |
5.1 |
||||||
|
U.S. |
17.7 |
28.6 |
5.8 |
||||||
|
International |
5.4 |
6.4 |
4.8 |
||||||
|
Diagnostics |
|||||||||
|
Second Quarter 2023 Results (2Q23) |
|||||||||
|
Sales 2Q23 ($ in millions) |
Total |
Core Laboratory |
Molecular |
Point of Care |
Rapid |
||||
|
U.S. |
961 |
311 |
43 |
99 |
508 |
||||
|
International |
1,356 |
982 |
98 |
43 |
233 |
||||
|
Total reported |
2,317 |
1,293 |
141 |
142 |
741 |
||||
|
% Change vs. 2Q22 |
|||||||||
|
U.S. |
(60.7) |
8.6 |
(40.1) |
(2.3) |
(74.4) |
||||
|
International |
(26.8) |
5.1 |
(29.9) |
13.1 |
(68.5) |
||||
|
Total reported |
(46.0) |
5.9 |
(33.3) |
1.9 |
(72.8) |
||||
|
Impact of foreign exchange |
(1.3) |
(3.6) |
(1.2) |
(0.5) |
(0.5) |
||||
|
Organic |
(44.7) |
9.5 |
(32.1) |
2.4 |
(72.3) |
||||
|
Impact of COVID-19 testing sales (3) |
(51.8) |
(0.6) |
(30.8) |
— |
(75.6) |
||||
|
Organic (excluding COVID-19 tests) |
7.1 |
10.1 |
(1.3) |
2.4 |
3.3 |
||||
|
U.S. |
5.2 |
9.4 |
3.4 |
(2.3) |
4.0 |
||||
|
International |
8.2 |
10.4 |
(3.1) |
15.2 |
2.3 |
||||
As expected, Diagnostics sales growth in the second quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales3. Worldwide COVID-19 testing sales were $263 million in the second quarter of 2023 compared to $2.324 billion in the second quarter of the prior year.
Excluding COVID-19 testing-related sales, global Diagnostics sales increased 4.3 percent on a reported basis and 7.1 percent on an organic basis.
|
First Half 2023 Results (1H23) |
|||||||||
|
Sales 1H23 ($ in millions) |
Total |
Core Laboratory |
Molecular |
Point of Care |
Rapid |
||||
|
U.S. |
2,296 |
600 |
90 |
192 |
1,414 |
||||
|
International |
2,709 |
1,875 |
198 |
84 |
552 |
||||
|
Total reported |
5,005 |
2,475 |
288 |
276 |
1,966 |
||||
|
% Change vs. 1H22 |
|||||||||
|
U.S. |
(55.4) |
8.2 |
(63.2) |
0.1 |
(66.0) |
||||
|
International |
(38.4) |
1.3 |
(48.9) |
11.2 |
(73.5) |
||||
|
Total reported |
(47.6) |
2.9 |
(54.4) |
3.2 |
(68.5) |
||||
|
Impact of foreign exchange |
(1.6) |
(4.4) |
(1.1) |
(0.8) |
(0.6) |
||||
|
Organic |
(46.0) |
7.3 |
(53.3) |
4.0 |
(67.9) |
||||
|
Impact of COVID-19 testing sales (3) |
(51.7) |
(1.3) |
(38.8) |
— |
(73.6) |
||||
|
Organic (excluding COVID-19 tests) |
5.7 |
8.6 |
(14.5) |
4.0 |
5.7 |
||||
|
U.S. |
2.7 |
9.2 |
(21.0) |
0.1 |
1.5 |
||||
|
International |
7.5 |
8.5 |
(11.6) |
14.0 |
12.3 |
||||
|
*The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As |
|||||||||
|
Established Pharmaceuticals |
|||||
|
Second Quarter 2023 Results (2Q23) |
|||||
|
Sales 2Q23 ($ in millions) |
Total |
Key Emerging |
Other |
||
|
U.S. |
— |
— |
— |
||
|
International |
1,287 |
990 |
297 |
||
|
Total reported |
1,287 |
990 |
297 |
||
|
% Change vs. 2Q22 |
|||||
|
U.S. |
n/a |
n/a |
n/a |
||
|
International |
5.2 |
4.6 |
7.1 |
||
|
Total reported |
5.2 |
4.6 |
7.1 |
||
|
Impact of foreign exchange |
(7.4) |
(8.4) |
(4.4) |
||
|
Organic |
12.6 |
13.0 |
11.5 |
||
|
U.S. |
n/a |
n/a |
n/a |
||
|
International |
12.6 |
13.0 |
11.5 |
||
Established Pharmaceuticals sales increased 5.2 percent on a reported basis and 12.6 percent on an organic basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 4.6 percent on a reported basis and 13.0 percent on an organic basis, led by growth in several geographies and therapeutic areas, including gastroenterology, women’s health, and central nervous system/pain management.
|
First Half 2023 Results (1H23) |
|||||
|
Sales 1H23 ($ in millions) |
Total |
Key Emerging |
Other |
||
|
U.S. |
— |
— |
— |
||
|
International |
2,476 |
1,902 |
574 |
||
|
Total reported |
2,476 |
1,902 |
574 |
||
|
% Change vs. 1H22 |
|||||
|
U.S. |
n/a |
n/a |
n/a |
||
|
International |
4.4 |
2.7 |
10.8 |
||
|
Total reported |
4.4 |
2.7 |
10.8 |
||
|
Impact of foreign exchange |
(7.5) |
(8.0) |
(5.5) |
||
|
Organic |
11.9 |
10.7 |
16.3 |
||
|
U.S. |
n/a |
n/a |
n/a |
||
|
International |
11.9 |
10.7 |
16.3 |
||
|
Medical Devices |
|||||||||||||||
|
Second Quarter 2023 Results (2Q23) |
|||||||||||||||
|
Sales 2Q23 ($ in millions) |
Total |
Rhythm |
Electro- physiology |
Heart |
Vascular |
Structural |
Neuro- |
Diabetes |
|||||||
|
U.S. |
1,913 |
269 |
245 |
226 |
264 |
219 |
185 |
505 |
|||||||
|
International |
2,382 |
314 |
308 |
69 |
451 |
279 |
42 |
919 |
|||||||
|
Total reported |
4,295 |
583 |
553 |
295 |
715 |
498 |
227 |
1,424 |
|||||||
|
% Change vs. 2Q22 |
|||||||||||||||
|
U.S. |
13.3 |
2.0 |
8.8 |
8.9 |
15.4 |
5.9 |
17.6 |
26.6 |
|||||||
|
International |
13.6 |
10.3 |
18.7 |
11.9 |
6.1 |
19.8 |
5.1 |
15.8 |
|||||||
|
Total reported |
13.5 |
6.3 |
14.1 |
9.6 |
9.3 |
13.3 |
15.1 |
19.4 |
|||||||
|
Impact of foreign exchange |
(1.9) |
(1.9) |
(2.8) |
(0.3) |
(2.3) |
(1.5) |
(1.1) |
(2.0) |
|||||||
|
Impact of CSI acquisition |
1.2 |
— |
— |
— |
6.6 |
— |
— |
— |
|||||||
|
Organic |
14.2 |
8.2 |
16.9 |
9.9 |
5.0 |
14.8 |
16.2 |
21.4 |
|||||||
|
U.S. |
11.0 |
2.0 |
8.8 |
8.9 |
(1.9) |
5.9 |
17.6 |
26.6 |
|||||||
|
International |
16.8 |
14.0 |
23.9 |
13.2 |
8.7 |
22.6 |
10.5 |
18.8 |
|||||||
Worldwide Medical Devices sales increased 13.5 percent on a reported basis and 14.2 percent on an organic basis in the second quarter. Sales growth was led by double-digit organic growth in Diabetes Care, Electrophysiology, Structural Heart and Neuromodulation. Several recently launched products and new indications contributed to the strong performance, including Amplatzer® Amulet®, Navitor®, TriClip®, and Aveir™.
In Electrophysiology, internationally, sales grew high-teens on a reported basis and more than 20 percent on an organic basis, which includes high-teens growth in Europe.
In Diabetes Care, FreeStyle Libre sales were $1.3 billion, which represents sales growth of 22.9 percent on a reported basis and 24.7 percent on an organic basis.
|
First Half 2023 Results (1H23) |
|||||||||||||||
|
Sales 1H23 ($ in millions) |
Total |
Rhythm |
Electro- physiology |
Heart |
Vascular |
Structural |
Neuro- |
Diabetes |
|||||||
|
U.S. |
3,691 |
529 |
483 |
444 |
482 |
429 |
340 |
984 |
|||||||
|
International |
4,504 |
581 |
575 |
132 |
850 |
530 |
83 |
1,753 |
|||||||
|
Total reported |
8,195 |
1,110 |
1,058 |
576 |
1,332 |
959 |
423 |
2,737 |
|||||||
|
% Change vs. 1H22 |
|||||||||||||||
|
U.S. |
14.2 |
3.2 |
9.4 |
10.0 |
10.3 |
8.1 |
13.2 |
32.7 |
|||||||
|
International |
8.6 |
3.6 |
8.7 |
14.1 |
1.8 |
16.8 |
9.1 |
11.2 |
|||||||
|
Total reported |
11.0 |
3.4 |
9.0 |
10.9 |
4.7 |
12.8 |
12.4 |
18.1 |
|||||||
|
Impact of foreign exchange |
(2.9) |
(2.8) |
(3.8) |
(0.8) |
(3.1) |
(2.7) |
(1.4) |
(3.1) |
|||||||
|
Impact of CSI acquisition |
0.6 |
— |
— |
— |
3.4 |
— |
— |
— |
|||||||
|
Organic |
13.3 |
6.2 |
12.8 |
11.7 |
4.4 |
15.5 |
13.8 |
21.2 |
|||||||
|
U.S. |
12.9 |
3.2 |
9.4 |
10.0 |
1.3 |
8.1 |
13.2 |
32.7 |
|||||||
|
International |
13.7 |
8.9 |
15.7 |
17.4 |
6.1 |
22.0 |
16.1 |
15.8 |
|||||||
|
*The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, |
|||||||||||||||
ABBOTT’S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2023 diluted earnings per share under GAAP of $3.02 to $3.22. Abbott forecasts specified items for the full-year 2023 of $1.28 per share primarily related to intangible amortization, costs associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.30 to $4.50 for the full-year 2023.
ABBOTT DECLARES 398TH CONSECUTIVE QUARTERLY DIVIDEND
On June 9, 2023, the board of directors of Abbott declared the company’s quarterly dividend of $0.51 per share. Abbott’s cash dividend is payable August 15, 2023, to shareholders of record at the close of business on July 14, 2023.
Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8:30 a.m. Central time today. An archived edition of the webcast will be available later in the day.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
|
1 |
For the full-year 2022, COVID-19 testing-related sales were $8.368 billion and total worldwide sales were $43.653 billion. |
|
2 |
Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. |
|
3 |
Diagnostic sales and COVID-19 testing-related sales in 2023 and 2022 are summarized below: |
|
Sales 2Q23 |
COVID Tests Sales 2Q23 |
|||||||||||
|
($ in millions) |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||
|
Total Diagnostics |
961 |
1,356 |
2,317 |
216 |
47 |
263 |
||||||
|
Core Laboratory |
311 |
982 |
1,293 |
2 |
3 |
5 |
||||||
|
Molecular |
43 |
98 |
141 |
4 |
4 |
8 |
||||||
|
Rapid Diagnostics |
508 |
233 |
741 |
210 |
40 |
250 |
||||||
|
Sales 2Q22 |
COVID Tests Sales 2Q22 |
|||||||||||
|
($ in millions) |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||
|
Total Diagnostics |
2,441 |
1,853 |
4,294 |
1,732 |
592 |
2,324 |
||||||
|
Core Laboratory |
287 |
934 |
1,221 |
3 |
9 |
12 |
||||||
|
Molecular |
71 |
141 |
212 |
34 |
41 |
75 |
||||||
|
Rapid Diagnostics |
1,982 |
740 |
2,722 |
1,695 |
542 |
2,237 |
||||||
|
Sales 1H23 |
COVID Tests Sales 1H23 |
|||||||||||
|
($ in millions) |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||
|
Total Diagnostics |
2,296 |
2,709 |
5,005 |
824 |
169 |
993 |
||||||
|
Core Laboratory |
600 |
1,875 |
2,475 |
4 |
7 |
11 |
||||||
|
Molecular |
90 |
198 |
288 |
14 |
14 |
28 |
||||||
|
Rapid Diagnostics |
1,414 |
552 |
1,966 |
806 |
148 |
954 |
||||||
|
Sales 1H22 |
COVID Tests Sales 1H22 |
|||||||||||
|
($ in millions) |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||
|
Total Diagnostics |
5,153 |
4,398 |
9,551 |
3,719 |
1,908 |
5,628 |
||||||
|
Core Laboratory |
555 |
1,850 |
2,405 |
8 |
32 |
40 |
||||||
|
Molecular |
243 |
389 |
632 |
148 |
173 |
321 |
||||||
|
Rapid Diagnostics |
4,163 |
2,084 |
6,247 |
3,563 |
1,703 |
5,267 |
||||||
|
Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Second Quarter Ended June 30, 2023 and 2022 (in millions, except per share data) (unaudited) |
||||||
|
2Q23 |
2Q22 |
% Change |
||||
|
Net Sales |
$9,978 |
$11,257 |
(11.4) |
|||
|
Cost of products sold, excluding amortization expense |
4,483 |
4,933 |
(9.1) |
|||
|
Amortization of intangible assets |
498 |
507 |
(1.7) |
|||
|
Research and development |
715 |
684 |
4.5 |
|||
|
Selling, general, and administrative |
2,740 |
2,757 |
(0.6) |
|||
|
Total Operating Cost and Expenses |
8,436 |
8,881 |
(5.0) |
|||
|
Operating Earnings |
1,542 |
2,376 |
(35.1) |
|||
|
Interest expense, net |
61 |
106 |
(41.7) |
|||
|
Net foreign exchange (gain) loss |
21 |
— |
n/m |
|||
|
Other (income) expense, net |
(176) |
(82) |
115.9 |
|||
|
Earnings before taxes |
1,636 |
2,352 |
(30.4) |
|||
|
Taxes on earnings |
261 |
334 |
(22.0) |
1) |
||
|
Net Earnings |
$1,375 |
$2,018 |
(31.8) |
|||
|
Net Earnings excluding Specified Items, as described below |
$1,893 |
$2,542 |
(25.5) |
2) |
||
|
Diluted Earnings per Common Share |
$0.78 |
$1.14 |
(31.6) |
|||
|
Diluted Earnings per Common Share, excluding Specified Items, as described below |
$1.08 |
$1.43 |
(24.5) |
2) |
||
|
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options |
1,750 |
1,765 |
||||
|
NOTES: |
|
|
See table titled “Non-GAAP Reconciliation of Financial Information” for an explanation of certain non-GAAP financial information. |
|
|
n/m = Percent change is not meaningful. |
|
|
See footnotes on the following below. |
|
|
1) |
2023 Taxes on Earnings includes the recognition of approximately $40 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
|
2) |
2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $518 million, or $0.30 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. |
|
2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $524 million, or $0.29 per share, for intangible amortization, charges related to a voluntary recall and other net expenses primarily associated with acquisitions. |
|
|
Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Half Ended June 30, 2023 and 2022 (in millions, except per share data) (unaudited) |
||||||
|
1H23 |
1H22 |
% Change |
||||
|
Net Sales |
$19,725 |
$23,152 |
(14.8) |
|||
|
Cost of products sold, excluding amortization expense |
8,814 |
9,920 |
(11.2) |
|||
|
Amortization of intangible assets |
989 |
1,019 |
(2.9) |
|||
|
Research and development |
1,369 |
1,381 |
(0.9) |
|||
|
Selling, general, and administrative |
5,502 |
5,544 |
(0.8) |
|||
|
Total Operating Cost and Expenses |
16,674 |
17,864 |
(6.7) |
|||
|
Operating Earnings |
3,051 |
5,288 |
(42.3) |
|||
|
Interest expense, net |
113 |
223 |
(49.2) |
|||
|
Net foreign exchange (gain) loss |
27 |
(3) |
n/m |
|||
|
Other (income) expense, net |
(287) |
(160) |
79.3 |
|||
|
Earnings before taxes |
3,198 |
5,228 |
(38.8) |
|||
|
Taxes on earnings |
505 |
763 |
(33.8) |
1) |
||
|
Net Earnings |
$2,693 |
$4,465 |
(39.7) |
|||
|
Net Earnings excluding Specified Items, as described below |
$3,708 |
$5,619 |
(34.0) |
2) |
||
|
Diluted Earnings per Common Share |
$1.53 |
$2.51 |
(39.0) |
|||
|
Diluted Earnings per Common Share, excluding Specified Items, as described below |
$2.11 |
$3.16 |
(33.2) |
2) |
||
|
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options |
1,751 |
1,770 |
||||
|
NOTES: |
|
|
See table titled “Non-GAAP Reconciliation of Financial Information” for an explanation of certain non-GAAP financial information. |
|
|
n/m = Percent change is not meaningful. |
|
|
See footnotes on the following below. |
|
|
1) |
2023 Taxes on Earnings includes the recognition of approximately $62 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
|
2022 Taxes on Earnings includes the recognition of approximately $27 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $32 million in excess tax benefits associated with share-based compensation. |
|
|
2) |
2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.015 billion, or $0.58 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. |
|
2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.154 billion, or $0.65 per share, for intangible amortization, charges related to a voluntary recall and other net expenses primarily associated with acquisitions. |
|
|
Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Second Quarter Ended June 30, 2023 and 2022 (in millions, except per share data) (unaudited) |
|||||
|
2Q23 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 498 |
$ (498) |
$ — |
||
|
Gross Margin |
4,997 |
529 |
5,526 |
||
|
R&D |
715 |
(72) |
643 |
||
|
SG&A |
2,740 |
(22) |
2,718 |
||
|
Other (income) expense, net |
(176) |
57 |
(119) |
||
|
Earnings before taxes |
1,636 |
566 |
2,202 |
||
|
Taxes on Earnings |
261 |
48 |
309 |
||
|
Net Earnings |
1,375 |
518 |
1,893 |
||
|
Diluted Earnings per Share |
$ 0.78 |
$ 0.30 |
$ 1.08 |
||
Specified items reflect intangible amortization expense of $498 million and other net expenses of $68 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items.
|
2Q22 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 507 |
$ (507) |
$ — |
||
|
Gross Margin |
5,817 |
563 |
6,380 |
||
|
R&D |
684 |
(32) |
652 |
||
|
SG&A |
2,757 |
(14) |
2,743 |
||
|
Other (income) expense, net |
(82) |
(12) |
(94) |
||
|
Earnings before taxes |
2,352 |
621 |
2,973 |
||
|
Taxes on Earnings |
334 |
97 |
431 |
||
|
Net Earnings |
2,018 |
524 |
2,542 |
||
|
Diluted Earnings per Share |
$ 1.14 |
$ 0.29 |
$ 1.43 |
||
Specified items reflect intangible amortization expense of $507 million and other net expenses of $114 million that includes costs associated with a product recall, acquisitions, and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items.
|
Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information First Half Ended June 30, 2023 and 2022 (in millions, except per share data) (unaudited) |
|||||
|
1H23 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 989 |
$ (989) |
$ — |
||
|
Gross Margin |
9,922 |
1,049 |
10,971 |
||
|
R&D |
1,369 |
(98) |
1,271 |
||
|
SG&A |
5,502 |
(24) |
5,478 |
||
|
Other (income) expense, net |
(287) |
57 |
(230) |
||
|
Earnings before taxes |
3,198 |
1,114 |
4,312 |
||
|
Taxes on Earnings |
505 |
99 |
604 |
||
|
Net Earnings |
2,693 |
1,015 |
3,708 |
||
|
Diluted Earnings per Share |
$ 1.53 |
$ 0.58 |
$ 2.11 |
||
Specified items reflect intangible amortization expense of $989 million and other net expenses of $125 million associated with restructuring actions, costs associated with acquisitions and other expenses. See table titled “Details of Specified Items” for additional details regarding specified items.
|
1H22 |
|||||
|
As Reported |
Specified |
As Adjusted |
|||
|
Intangible Amortization |
$ 1,019 |
$ (1,019) |
$ — |
||
|
Gross Margin |
12,213 |
1,199 |
13,412 |
||
|
R&D |
1,381 |
(65) |
1,316 |
||
|
SG&A |
5,544 |
(53) |
5,491 |
||
|
Other (income) expense, net |
(160) |
(27) |
(187) |
||
|
Earnings before taxes |
5,228 |
1,344 |
6,572 |
||
|
Taxes on Earnings |
763 |
190 |
953 |
||
|
Net Earnings |
4,465 |
1,154 |
5,619 |
||
|
Diluted Earnings per Share |
$ 2.51 |
$ 0.65 |
$ 3.16 |
||
Specified items reflect intangible amortization expense of $1.019 billion and other net expenses of $325 million that includes costs associated with a product recall, acquisitions, and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items.
A reconciliation of the second-quarter tax rates for 2023 and 2022 is shown below:
|
2Q23 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 1,636 |
$ 261 |
15.9 % |
1) |
||
|
Specified items |
566 |
48 |
||||
|
Excluding specified items |
$ 2,202 |
$ 309 |
14.0 % |
|||
|
2Q22 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 2,352 |
$ 334 |
14.2 % |
|||
|
Specified items |
621 |
97 |
||||
|
Excluding specified items |
$ 2,973 |
$ 431 |
14.5 % |
|||
|
1) |
2023 Taxes on Earnings includes the recognition of approximately $40 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
|
A reconciliation of the year-to-date tax rates for 2023 and 2022 is shown below: |
||||||
|
1H23 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 3,198 |
$ 505 |
15.8 % |
2) |
||
|
Specified items |
1,114 |
99 |
||||
|
Excluding specified items |
$ 4,312 |
$ 604 |
14.0 % |
|||
|
1H22 |
||||||
|
($ in millions) |
Pre-Tax Income |
Taxes on Earnings |
Tax Rate |
|||
|
As reported (GAAP) |
$ 5,228 |
$ 763 |
14.6 % |
3) |
||
|
Specified items |
1,344 |
190 |
||||
|
Excluding specified items |
$ 6,572 |
$ 953 |
14.5 % |
|||
|
2) |
2023 Taxes on Earnings includes the recognition of approximately $62 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
|
3) |
2022 Taxes on Earnings includes the recognition of approximately $27 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $32 million in excess tax benefits associated with share-based compensation. |
|
Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation Second Quarter and First Half Ended June 30, 2023 and 2022 ($ in millions) (unaudited) |
|||||||||||||||||||||||||||
|
2Q23 |
2Q22 |
% Change vs. 2Q22 |
|||||||||||||||||||||||||
|
Non-GAAP |
|||||||||||||||||||||||||||
|
Abbott |
Impact of CSI |
Impact from |
Adjusted |
Abbott |
Impact from |
Adjusted |
Reported |
Adjusted |
Organic |
||||||||||||||||||
|
Total Company |
9,978 |
(43) |
(29) |
9,906 |
11,257 |
(39) |
11,218 |
(11.4) |
(11.7) |
(9.2) |
|||||||||||||||||
|
U.S. |
3,758 |
(39) |
— |
3,719 |
4,892 |
— |
4,892 |
(23.2) |
(24.0) |
(24.0) |
|||||||||||||||||
|
Intl |
6,220 |
(4) |
(29) |
6,187 |
6,365 |
(39) |
6,326 |
(2.3) |
(2.2) |
2.2 |
|||||||||||||||||
|
Total Nutrition |
2,076 |
— |
(29) |
2,047 |
1,953 |
(39) |
1,914 |
6.3 |
6.9 |
9.9 |
|||||||||||||||||
|
U.S. |
881 |
— |
— |
881 |
761 |
— |
761 |
15.7 |
15.7 |
15.7 |
|||||||||||||||||
|
Intl |
1,195 |
— |
(29) |
1,166 |
1,192 |
(39) |
1,153 |
0.3 |
1.2 |
6.1 |
|||||||||||||||||
|
Pediatric Nutrition |
1,024 |
— |
(29) |
995 |
925 |
(39) |
886 |
10.6 |
12.2 |
14.5 |
|||||||||||||||||
|
U.S. |
507 |
— |
— |
507 |
413 |
— |
413 |
22.5 |
22.5 |
22.5 |
|||||||||||||||||
|
Intl |
517 |
— |
(29) |
488 |
512 |
(39) |
473 |
1.1 |
3.3 |
7.5 |
|||||||||||||||||
|
Total Medical Devices |
4,295 |
(43) |
— |
4,252 |
3,785 |
— |
3,785 |
13.5 |
12.3 |
14.2 |
|||||||||||||||||
|
U.S. |
1,913 |
(39) |
— |
1,874 |
1,688 |
— |
1,688 |
13.3 |
11.0 |
11.0 |
|||||||||||||||||
|
Intl |
2,382 |
(4) |
— |
2,378 |
2,097 |
— |
2,097 |
13.6 |
13.4 |
16.8 |
|||||||||||||||||
|
Vascular |
715 |
(43) |
— |
672 |
653 |
— |
653 |
9.3 |
2.7 |
5.0 |
|||||||||||||||||
|
U.S. |
264 |
(39) |
— |
225 |
228 |
— |
228 |
15.4 |
(1.9) |
(1.9) |
|||||||||||||||||
|
Intl |
451 |
(4) |
— |
447 |
425 |
— |
425 |
6.1 |
5.2 |
8.7 |
|||||||||||||||||
|
1H23 |
1H22 |
% Change vs. 1H22 |
||||||||||||||||||||||||||
|
Non-GAAP |
||||||||||||||||||||||||||||
|
Abbott |
Impact of CSI |
Impact from |
Adjusted |
Abbott |
Impact from |
Adjusted |
Reported |
Adjusted |
Organic |
|||||||||||||||||||
|
Total Company |
19,725 |
(43) |
(37) |
19,645 |
23,152 |
(91) |
23,061 |
(14.8) |
(14.8) |
(11.9) |
||||||||||||||||||
|
U.S. |
7,686 |
(39) |
— |
7,647 |
9,829 |
— |
9,829 |
(21.8) |
(22.2) |
(22.2) |
||||||||||||||||||
|
Intl |
12,039 |
(4) |
(37) |
11,998 |
13,323 |
(91) |
13,232 |
(9.6) |
(9.3) |
(4.3) |
||||||||||||||||||
|
Total Nutrition |
4,043 |
— |
(37) |
4,006 |
3,847 |
(91) |
3,756 |
5.1 |
6.7 |
10.1 |
||||||||||||||||||
|
U.S. |
1,693 |
— |
— |
1,693 |
1,438 |
— |
1,438 |
17.7 |
17.7 |
17.7 |
||||||||||||||||||
|
Intl |
2,350 |
— |
(37) |
2,313 |
2,409 |
(91) |
2,318 |
(2.4) |
(0.1) |
5.4 |
||||||||||||||||||
|
Pediatric Nutrition |
1,948 |
— |
(37) |
1,911 |
1,772 |
(91) |
1,681 |
9.9 |
13.7 |
16.3 |
||||||||||||||||||
|
U.S. |
966 |
— |
— |
966 |
751 |
— |
751 |
28.6 |
28.6 |
28.6 |
||||||||||||||||||
|
Intl |
982 |
— |
(37) |
945 |
1,021 |
(91) |
930 |
(3.8) |
1.8 |
6.4 |
||||||||||||||||||
|
Total Medical Devices |
8,195 |
(43) |
— |
8,152 |
7,379 |
— |
7,379 |
11.0 |
10.4 |
13.3 |
||||||||||||||||||
|
U.S. |
3,691 |
(39) |
— |
3,652 |
3,233 |
— |
3,233 |
14.2 |
12.9 |
12.9 |
||||||||||||||||||
|
Intl |
4,504 |
(4) |
— |
4,500 |
4,146 |
— |
4,146 |
8.6 |
8.5 |
13.7 |
||||||||||||||||||
|
Vascular |
1,332 |
(43) |
— |
1,289 |
1,272 |
— |
1,272 |
4.7 |
1.3 |
4.4 |
||||||||||||||||||
|
U.S. |
482 |
(39) |
— |
443 |
437 |
— |
437 |
10.3 |
1.3 |
1.3 |
||||||||||||||||||
|
Intl |
850 |
(4) |
— |
846 |
835 |
— |
835 |
1.8 |
1.3 |
6.1 |
||||||||||||||||||
|
(a) Reflects the impact of the acquisition of Cardiovascular Systems, Inc. (CSI) on April 27, 2023. |
||||||||||||||||||||||||||||
|
(b) Reflects the impact of exiting the pediatric nutrition business in China. This action was initiated in December 2022. |
||||||||||||||||||||||||||||
|
Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2023 (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ 7 |
$ 11 |
$ 498 |
$ 13 |
$ 529 |
||||
|
R&D |
(8) |
7 |
— |
(71) |
(72) |
||||
|
SG&A |
(17) |
(2) |
— |
(3) |
(22) |
||||
|
Other (income) expense, net |
47 |
— |
— |
10 |
57 |
||||
|
Earnings before taxes |
$ (15) |
$ 6 |
$ 498 |
$ 77 |
566 |
||||
|
Taxes on Earnings (d) |
48 |
||||||||
|
Net Earnings |
$ 518 |
||||||||
|
Diluted Earnings per Share |
$ 0.30 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” |
|
|
a) |
Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. These costs were more than offset by fair value adjustments to contingent consideration related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the European Union’s Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible asset impairments. |
|
d) |
Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. |
|
Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2022 (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ 20 |
$ (6) |
$ 507 |
$ 42 |
$ 563 |
||||
|
R&D |
(5) |
— |
— |
(27) |
(32) |
||||
|
SG&A |
(7) |
— |
— |
(7) |
(14) |
||||
|
Other (income) expense, net |
(4) |
— |
— |
(8) |
(12) |
||||
|
Earnings before taxes |
$ 36 |
$ (6) |
$ 507 |
$ 84 |
621 |
||||
|
Taxes on Earnings (d) |
97 |
||||||||
|
Net Earnings |
$ 524 |
||||||||
|
Diluted Earnings per Share |
$ 0.29 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” |
|
|
a) |
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott’s manufacturing network for COVID-19 diagnostic tests. |
|
c) |
Other includes costs related to a voluntary recall within the Nutrition segment and incremental costs to comply with the MDR and IVDR regulations for previously approved products. |
|
d) |
Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation. |
|
Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2023 (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ 12 |
$ 32 |
$ 989 |
$ 16 |
$ 1,049 |
||||
|
R&D |
(12) |
8 |
— |
(94) |
(98) |
||||
|
SG&A |
(21) |
(6) |
— |
3 |
(24) |
||||
|
Other (income) expense, net |
41 |
— |
— |
16 |
57 |
||||
|
Earnings before taxes |
$ 4 |
$ 30 |
$ 989 |
$ 91 |
1,114 |
||||
|
Taxes on Earnings (d) |
99 |
||||||||
|
Net Earnings |
$ 1,015 |
||||||||
|
Diluted Earnings per Share |
$ 0.58 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” |
|
|
a) |
Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. These costs were partially offset by fair value adjustments to contingent consideration related to business acquisitions. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
|
c) |
Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments. |
|
d) |
Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. |
|
Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2022 (in millions, except per share data) (unaudited) |
|||||||||
|
Acquisition or Divestiture- related (a) |
Restructuring and Cost Reduction Initiatives (b) |
Intangible Amortization |
Other (c) |
Total Specifieds |
|||||
|
Gross Margin |
$ 41 |
$ (12) |
$ 1,019 |
$ 151 |
$ 1,199 |
||||
|
R&D |
(7) |
(1) |
— |
(57) |
(65) |
||||
|
SG&A |
(18) |
— |
— |
(35) |
(53) |
||||
|
Other (income) expense, net |
(11) |
— |
— |
(16) |
(27) |
||||
|
Earnings before taxes |
$ 77 |
$ (11) |
$ 1,019 |
$ 259 |
1,344 |
||||
|
Taxes on Earnings (d) |
190 |
||||||||
|
Net Earnings |
$ 1,154 |
||||||||
|
Diluted Earnings per Share |
$ 0.65 |
||||||||
|
The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” |
|
|
a) |
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott’s manufacturing network for COVID-19 diagnostic tests. |
|
c) |
Other includes charges related to a voluntary recall within the Nutrition segment and incremental costs to comply with the MDR and IVDR regulations for previously approved products. |
|
d) |
Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation and net tax expense as a result of the resolution of various tax positions related to prior years. |
SOURCE Abbott
